North Dakota State Investment Board Invests $3.91 Million in Bristol Myers Squibb Company $BMY

North Dakota State Investment Board bought a new position in Bristol Myers Squibb Company (NYSE:BMY) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 72,479 shares of the biopharmaceutical company’s stock, valued at approximately $3,910,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. waypoint wealth counsel purchased a new stake in shares of Bristol Myers Squibb during the fourth quarter worth about $1,194,000. Phoenix Financial Ltd. grew its holdings in shares of Bristol Myers Squibb by 110.1% during the third quarter. Phoenix Financial Ltd. now owns 106,154 shares of the biopharmaceutical company’s stock worth $4,789,000 after buying an additional 55,624 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Bristol Myers Squibb by 4.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,211,845 shares of the biopharmaceutical company’s stock worth $99,754,000 after buying an additional 93,528 shares in the last quarter. Oppenheimer Asset Management Inc. grew its holdings in shares of Bristol Myers Squibb by 6.4% during the third quarter. Oppenheimer Asset Management Inc. now owns 531,538 shares of the biopharmaceutical company’s stock worth $23,972,000 after buying an additional 32,005 shares in the last quarter. Finally, M&G PLC grew its holdings in shares of Bristol Myers Squibb by 1.4% during the third quarter. M&G PLC now owns 6,885,188 shares of the biopharmaceutical company’s stock worth $309,833,000 after buying an additional 97,063 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on BMY shares. Cantor Fitzgerald boosted their target price on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Morgan Stanley restated an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a report on Friday, February 6th. Bank of America lowered their target price on shares of Bristol Myers Squibb from $68.00 to $67.00 and set a “buy” rating for the company in a report on Thursday, April 9th. Guggenheim restated a “buy” rating and issued a $72.00 target price on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Eight research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $61.31.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb’s $15.2 billion collaboration and licensing deal with Hengrui Pharma expands its pipeline with 13 early-stage programs, a major long-term growth catalyst. Bristol-Myers Strikes $15.2 Billion China Drug Deal
• Positive Sentiment: Zacks Research raised earnings estimates for FY2026, FY2027, FY2028 and several quarterly periods, suggesting improved profitability expectations for BMY. MarketBeat Bristol Myers Squibb estimates update
• Positive Sentiment: Tempus expanded its strategic collaboration with Bristol Myers Squibb to use AI and real-world data to improve clinical development success in oncology and neuroscience. Tempus expands strategic collaboration with Bristol Myers Squibb
• Positive Sentiment: Tigerlily Foundation announced a collaboration with Bristol Myers Squibb to expand clinical trial access and reduce participation barriers, supporting the company’s ESG and patient-access profile. Tigerlily Foundation collaborates with Bristol Myers Squibb
• Neutral Sentiment: Bristol Myers Squibb presented at the Bank of America Global Healthcare Conference, which is typically informational rather than a direct stock-moving event. Bristol-Myers Squibb Company presents at conference transcript
• Neutral Sentiment: Analyst commentary on BMY’s valuation and “buy, sell, or hold” status adds context, but it does not appear to be a new fundamental catalyst. Bristol-Myers Squibb buy sell or hold post Q1 earnings
• Negative Sentiment: One article highlighted a recent pullback in BMY shares, reminding investors that momentum has been uneven despite the recent rally. Bristol-Myers Squibb Stock Falls 3.9% After May 2026 Pullback

Bristol Myers Squibb Price Performance

BMY opened at $57.04 on Monday. The company has a quick ratio of 1.28, a current ratio of 1.42 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $62.89. The company has a 50 day moving average of $58.63 and a two-hundred day moving average of $55.43. The company has a market cap of $116.48 billion, a P/E ratio of 16.02, a P/E/G ratio of 0.16 and a beta of 0.26.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion during the quarter, compared to the consensus estimate of $10.93 billion. During the same period in the previous year, the firm earned $1.80 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, analysts expect that Bristol Myers Squibb Company will post 6.31 earnings per share for the current year.

Bristol Myers Squibb Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, May 1st. Shareholders of record on Thursday, April 2nd were paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date was Thursday, April 2nd. Bristol Myers Squibb’s payout ratio is currently 70.79%.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total transaction of $1,850,100.00. Following the completion of the sale, the executive vice president directly owned 159,248 shares in the company, valued at $9,820,824.16. The trade was a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 0.05% of the stock is currently owned by corporate insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.